Carelon Research perspectives
Insights intended to advance evidence-based healthcare
A conversation with the co-founders of Carelon Research (formerly HealthCore, Inc.): Mark Cziraky and Marcus Wilson
January 2022
The co-founders of Carelon Research (formerly HealthCore, Inc.) reflect on the journey from 1996 and the recent brand transition to Carelon Research.
Carelon Research impact study: Innovative approaches to gathering the patient perspective
July 2022
The patient-centered research team at Carelon Research goes beyond numbers to inform meaningful research solutions with rich, in-depth insights.
Clinical oncology research solutions
July 2022
The data environment, relationships, and research expertise at Carelon Research position us to deliver high-quality, actionable results, saving you time and effort.
Causal inference for real-world evidence
July 2022
Carelon Research offers highly specialized scientists, access to a robust source of integrated real-world data, and decades of experience necessary for successfully employing these methods.
A letter from the president: Our next chapter
July 2022
HealthCore (now Carelon Research) is joining the Carelon family of companies under Elevance Health.
Carelon Research impact study: Using background incidence rates to inform vaccine safety
July 2022
This study provides context for potential safety events that may arise among children and adults vaccinated with a pneumococcal vaccine.
Carelon Research impact study: Validation of integrated claims and clinical oncology data
July 2022
Researchers at Carelon Research examined the validity of the CCQP data relative to information abstracted from the redacted medical records of breast, lung, and colorectal cancer patients.
What is causal inference and when do you need it?
July 2022
Causal inference is used to answer cause and effect research questions and yield estimates of effect (as opposed to associations).
Carelon Research impact study: Atenolol versus Losartan in children and young adults with Marfan Syndrome
April 2022
The Marfan study is one of several landmark studies to which Carelon Research has contributed statistical and regulatory oversight, and data and project management.
Carelon Research impact study: A Sentinel data partner and scientific collaborator
March 2022
From the time that the FDA began the Sentinel Initiative, Carelon Research has been a key data partner and collaborating institution.
Survey research: Elements of a “good” survey
January 2022
After determining that a survey is the best method for obtaining answers to their research questions, researchers should consider the elements of a “good” survey.
Carelon Research impact study: Cost effectiveness of a proteomic test for preterm birth prediction
November 2021
This study is one of the first economic evaluations using real-world data to assess the potential value of the PreTRM test for preterm birth risk in a commercially insured U.S. population.
What is real-world evidence and why is it important?
November 2021
Real-world data and real-world evidence are more than just buzzwords. They’re becoming increasingly important for informing healthcare decisions across a number of settings and stakeholders.
Carelon Research impact study: Topiramate use in pregnancy and the birth prevalence of oral clefts
August 2021
A collaborative study by Carelon Research and our partners found that first trimester exposure to topiramate is associated with an increased prevalence of oral clefts.
Carelon Research celebrates 25th anniversary of Founder’s Day: A letter from the president
July 2021
Twenty-five years have passed since we set out on this journey. Our mission to advance the derivation and utilization of real-world evidence continues.
Real-world evidence complements randomized clinical trials to enhance drug safety and effectiveness
February 2021
Carelon Research conducted one of the first real-world studies investigating the safety of palbociclib, the most widely prescribed CDK4/6 inhibitor in the treatment of HR+/HER2- advanced stage breast cancer.
Predictive modeling and machine learning: Sharpening the focus of real-world evidence in the age of precision medicine
April 2020
The use of statistical methods to develop better case-identifying algorithms enables use of claims databases to study rare diseases and other targeted indications.
The power of machine learning
October 2019
Machine learning combines advanced statistical methods with the results from validation studies to construct new case-identifying algorithms.
A leader in pediatric research for 30 years
October 2019
Since its founding, Carelon Research’s clinical research team has been deeply involved in conducting, and collaborating on, research with children and infants.
The value of pragmatic trials to regulators
October 2019
Regulatory agencies have expressed interest in using pragmatic trial-generated evidence in regulatory decision-making.
The value of pragmatic trials to life science product developers
October 2019
For the biopharmaceuticals industry, pragmatic trials uniquely offer solutions to address the growing demands of healthcare payers and policy makers.
The value of pragmatic trials to clinicians
October 2019
For clinicians, pragmatic trials generate evidence that enables better-informed decision making.
HEOR trends: Going broad and deep in real-world evidence
October 2019
Carelon Research has the data assets and expertise necessary for going broad and deep in real-world evidence generation.
The growing war against opioids
October 2019
As activities and significant events related to opioids, including abuse and misuse play out, safety and epidemiology research is providing insights into the effectiveness of these efforts.
